Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells.

ABSTRACT:

Background

Despite the progress made in the clinical management of metastatic melanoma, a patient's response to treatment cannot be fully predicted, and intrinsic or acquired resistance that is developed in most melanoma patients warrants further research efforts. In addition to genetic factors, microenvironmental input should be considered to explain the diversity of response to treatment among melanoma patients. In this study, we evaluated the impact of insulin on patient-derived BRAF^V600E melanoma cells, either untreated or treated with vemurafenib or trametinib, inhibitors of BRAF^V600 and MEK1/2, respectively.

Methods

Cells were cultured in serum-free conditions, either with or without insulin. The activity of the MAPK/ERK and PI3K/AKT pathways was

SUBMITTER: Osrodek M 

PROVIDER: S-EPMC7501594 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature